Cost drivers in the pharmacological treatment of interstitial lung disease.

ABSTRACT:

Introduction

Treatments of interstitial lung diseases (ILDs) mainly focus on disease stabilization and relief of symptoms by managing inflammation or suppressing fibrosis by (in part costly) drugs. To highlight economic burden of drug treatment in different ILD-subtypes we assessed cost trends and therewith-associated drivers.

Methods

Using data from the German, observational HILDA study we estimated adjusted mean medication costs over 36-month intervals using one- and two-part Generalized Estimating Equation (GEE) regression models with a gamma distribution and log link. Next, we determined factors associated with costs.

Results

In Idiopathic pulmonary fibrosis (IPF) mean per capita medication costs increased from €1442 before to €11,000€ at the end of study. In non-

SUBMITTER: Maqhuzu PN 

PROVIDER: S-EPMC8335870 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature